The causative agent of the coronavirus disease 2019 (COVID-19) – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – was first detected in Wuhan, China, in December 2019. To date, the virus ...
In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy of ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
The recombinant vector vaccines segment accounted for a market share of more than 11% in the global veterinary market in 2016. Recombinant vector vaccines mimic a natural process of infection, but ...
Since February 2021, very rare cases of thrombosis with thrombocytopenia syndrome, later named vaccine-induced immune thrombocytopenia and thrombosis (VITT) have been reported after receipt of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results